Handbook of Hematologic Malignancies

Handbook of Hematologic Malignancies 3rd Edition remains an indispensable resource for busy hematologists, hematologic oncologists, hematopathologists, oncology advanced practice providers, oncology nurses, and trainees. This significantly revised and completely updated edition is meticulously organized to provide concise, essential information on diagnosis, prognosis, therapeutic management, and clinical trial opportunities for each hematologic malignancy. Each chapter features detailed figures that illustrate the hematopathologic characteristics of diseases, along with tables designed to simplify the review of differential diagnoses, prognostic scoring systems, molecular profiles, and therapeutic options. This edition introduces a completely new set of challenging clinical cases, designed to rigorously test clinicians' knowledge of pathologic diagnosis and clinical presentation. With over 35 new FDA-approved indications since the second editionfeaturing groundbreaking advancements such as CAR-T therapythis handbook serves as a quick reference for practice-changing information on complex diagnostic dilemmas, frontline treatments, refractory scenarios, and relapse management. Purchase includes online access via most mobile devices or computers. Key Features: New chapters on precursor states in myeloid malignancies (CHIP/CCUS), familial/inherited risks of hematologic malignancies, CAR-T versus Bispecific Treatment, and mechanisms of CAR-T resistance. Entirely new unfolding clinical cases with board-style questions, enhancing critical thinking and knowledge application with every clinical chapter. Features updated chapters that concisely outline new standards of care and management considerations, accompanied by key references for further reading. Highlights essential diagnostic tools, including updated 2022 WHO and ICC classification systems, that aid in conducting critical differential diagnoses and resolving complex diagnostic dilemmas. Delivers key updates on potential practice-changing clinical trials and paradigm-shifting treatment considerations within each disease-based chapter, ensuring clinicians stay at the forefront of hematologic oncology.